Burkitt's lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(21 intermediate revisions by 4 users not shown)
Line 2: Line 2:
{{Burkitt's lymphoma}}
{{Burkitt's lymphoma}}


{{CMG}}; {{AE}} {{AS}}
{{CMG}}; {{AE}} {{AS}}, {{kakbar}}
==Overview==
==Overview==
The predominant therapy for Burkitt's lymphoma is [[chemotherapy]]. Adjunctive [[immunotherapy]] and [[stem cell transplantation]] may be required.
==Medical Therapy==
==Medical Therapy==
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive [[immunotherapy]] and [[stem cell transplantation]] may be required.<ref name="Cancer.ca">Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015</ref>
===Chemotherapy===
===Chemotherapy===
* Drug Regimen: (CODOX-M) [[Cyclophosphamide]], {{and}} [[Vincristine]], {{and}} [[Doxorubicin]], {{and}} [[Methotrexate]]
* [[Chemotherapeutic agent|Chemotherapeutic]] regimens for Burkitt's lymphoma include:<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref>
* Drug Regimen: (IVAC) [[Ifosfamide]] {{plus}} [[Mesna]], {{and}} [[Etoposide]], {{and}} [[Cytarabine]]  
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Methotrexate]] (CODOX-M)<ref name="pmid29741758">{{cite journal| author=Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K et al.| title=Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. | journal=Br J Haematol | year= 2018 | volume= 181 | issue= 6 | pages= 782-790 | pmid=29741758 | doi=10.1111/bjh.15262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29741758  }} </ref><ref name="pmid25957391">{{cite journal| author=Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E et al.| title=AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. | journal=Blood | year= 2015 | volume= 126 | issue= 2 | pages= 160-6 | pmid=25957391 | doi=10.1182/blood-2015-01-623900 | pmc=4497960 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25957391  }} </ref>
* Drug Regimen: (Hyper-CVAD) [[Cyclophosphamide]], {{and}} [[Vincristine]], {{and}} [[Doxorubicin]], {{and}} [[Dexamethasone]], {{and}} [[Methotrexate]], {{and}} [[Cytarabine]]
* [[Ifosfamide]] {{and}} [[Mesna]] {{and}} [[Etoposide]] {{and}} [[Cytarabine]] (IVAC)<ref name="BortzCoutsouvelis2015">{{cite journal|last1=Bortz|first1=H.|last2=Coutsouvelis|first2=J.|last3=Corallo|first3=C. E.|last4=Spencer|first4=A.|last5=Patil|first5=S.|title=Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease|journal=Journal of Clinical Pharmacy and Therapeutics|volume=40|issue=4|year=2015|pages=483–485|issn=02694727|doi=10.1111/jcpt.12293}}</ref><ref name="pmid25957391">{{cite journal| author=Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E et al.| title=AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. | journal=Blood | year= 2015 | volume= 126 | issue= 2 | pages= 160-6 | pmid=25957391 | doi=10.1182/blood-2015-01-623900 | pmc=4497960 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25957391  }} </ref>
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]] {{and}} [[Methotrexate]] {{and}} [[Cytarabine]] (Hyper-CVAD)<ref name="pmid20660823">{{cite journal| author=Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W et al.| title=Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. | journal=J Clin Oncol | year= 2010 | volume= 28 | issue= 24 | pages= 3880-9 | pmid=20660823 | doi=10.1200/JCO.2009.26.9456 | pmc=2940403 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20660823  }} </ref>
'''CNS prophylaxis'''
* There is a high risk that Burkitt's lymphoma will spread to the [[central nervous system]] ([[CNS]])
* CNS prophylaxis may involve giving [[intrathecal]] chemotherapy, high doses of systemic therapy, or both methods may be used<ref name="pmid27025508">{{cite journal| author=González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA et al.| title=Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. | journal=Ann Hematol | year= 2016 | volume= 95 | issue= 6 | pages= 893-9 | pmid=27025508 | doi=10.1007/s00277-016-2648-4 | pmc=4853453 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27025508  }} </ref>
* [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for [[CNS]] [[prophylaxis]]<ref name="pmid27846613">{{cite journal| author=Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C et al.| title=Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). | journal=Haematologica | year= 2017 | volume= 102 | issue= 2 | pages= 235-245 | pmid=27846613 | doi=10.3324/haematol.2016.149120 | pmc=5286932 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27846613  }} </ref>
===Biological therapy===
===Biological therapy===
* Monoclonal antibodies are a type of biological therapy that is effective in treating Burkitt's lymphoma
* [[Monoclonal antibodies]] are a type of biological therapy that is effective in treating Burkitt's lymphoma<ref name="pmid7031655">{{cite journal| author=Wiels J, Fellous M, Tursz T| title=Monoclonal antibody against a Burkitt lymphoma-associated antigen. | journal=Proc Natl Acad Sci U S A | year= 1981 | volume= 78 | issue= 10 | pages= 6485-8 | pmid=7031655 | doi= | pmc=349064 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7031655  }} </ref>
* [[Rituximab]] may be added to each of the above chemotherapy regimens
* [[Rituximab]] may be added to each of the above [[chemotherapy]] regimens<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref><ref name="pmid20660823">{{cite journal| author=Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W et al.| title=Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. | journal=J Clin Oncol | year= 2010 | volume= 28 | issue= 24 | pages= 3880-9 | pmid=20660823 | doi=10.1200/JCO.2009.26.9456 | pmc=2940403 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20660823  }} </ref>
===CNS prophylaxis===
* There is a high risk that Burkitt's lymphoma will spread to the central nervous system (CNS)
* CNS prophylaxis may involve giving intrathecal chemotherapy high doses of systemic therapy, or both methods may be used
* [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for CNS prophylaxis
===Stem cell transplant===
===Stem cell transplant===
* A Stem cell transplant may be offered to some people with Burkitt's lymphoma if their lymphoma returns or relapses after treatment
* A [[stem cell transplant]] may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref>
 


==References==
==References==
Line 31: Line 35:
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 23:26, 21 January 2019

Burkitt's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings

CT

MRI

Biopsy

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma medical therapy

CDC on Burkitt's lymphoma medical therapy

Burkitt's lymphoma medical therapy in the news

Blogs on Burkitt's lymphoma medical therapy

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2], Kamal Akbar, M.D.[3]

Overview

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.

Medical Therapy

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.[1]

Chemotherapy

CNS prophylaxis

Biological therapy

Stem cell transplant

  • A stem cell transplant may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.[2]


References

  1. Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
  2. 2.0 2.1 2.2 Jacobson, C.; LaCasce, A. (2014). "How I treat Burkitt lymphoma in adults". Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
  3. Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). "Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab". Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.
  4. 4.0 4.1 Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E; et al. (2015). "AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma". Blood. 126 (2): 160–6. doi:10.1182/blood-2015-01-623900. PMC 4497960. PMID 25957391.
  5. Bortz, H.; Coutsouvelis, J.; Corallo, C. E.; Spencer, A.; Patil, S. (2015). "Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease". Journal of Clinical Pharmacy and Therapeutics. 40 (4): 483–485. doi:10.1111/jcpt.12293. ISSN 0269-4727.
  6. 6.0 6.1 Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W; et al. (2010). "Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia". J Clin Oncol. 28 (24): 3880–9. doi:10.1200/JCO.2009.26.9456. PMC 2940403. PMID 20660823.
  7. González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA; et al. (2016). "Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial". Ann Hematol. 95 (6): 893–9. doi:10.1007/s00277-016-2648-4. PMC 4853453. PMID 27025508.
  8. Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). "Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)". Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.
  9. Wiels J, Fellous M, Tursz T (1981). "Monoclonal antibody against a Burkitt lymphoma-associated antigen". Proc Natl Acad Sci U S A. 78 (10): 6485–8. PMC 349064. PMID 7031655.

Template:Chromosomal abnormalities


Template:WikiDoc Sources